GI bleed nursing reference: assessment and interventions

Gastrointestinal bleeding ranges from a slow ooze discovered incidentally on lab work to a massive hemorrhage with hemodynamic collapse within minutes. Upper GI bleeding — defined as bleeding proximal to the ligament of Treitz — has an incidence of approximately 67 per 100,000 population per year with in-hospital mortality around 10%. Lower GI bleeding (distal to the ligament of Treitz) affects roughly 36 per 100,000 per year with mortality below 4%. Nurses are usually the first to recognize the early warning signs: tachycardia, postural hypotension, a change in stool character, or fresh blood in the NG aspirate. Catching these signals early and acting on them precisely is what this reference is designed to support.

This page covers upper and lower GI bleed pathophysiology, clinical presentations, systematic assessment, priority interventions, risk stratification, pre-procedure care, complications, and NCLEX-focused review points. For the underlying pathophysiology of ulcers, see the peptic ulcer disease nursing reference. For variceal bleeding in the context of portal hypertension, see the cirrhosis nursing reference.

Upper GI bleeding

Upper GI bleeding originates proximal to the ligament of Treitz — the suspensory ligament anchoring the duodenojejunal junction. The three primary anatomic sources are the esophagus, stomach, and duodenum. Upper GI bleeds account for approximately two-thirds of all GI hemorrhage cases and carry higher mortality than lower GI bleeds because the vessels supplying these structures are large-caliber.

Causes of upper GI bleeding

Peptic ulcer disease (PUD) is the most common cause, responsible for approximately 40% of upper GI bleeds. Gastric acid erodes through the mucosa into submucosal blood vessels. Posterior duodenal ulcers carry the highest hemorrhage risk because the ulcer erodes directly toward the gastroduodenal artery — a complication that produces massive, arterial hemorrhage. See the peptic ulcer disease nursing reference for full PUD pathophysiology and management.

Other causes in order of clinical frequency:

• Esophageal varices — dilated submucosal veins from portal hypertension. Variceal bleeds carry 15–25% mortality per episode and require a distinct management pathway (octreotide, antibiotics, banding). Cirrhosis is the underlying driver in the majority of cases. See the cirrhosis nursing reference for portal hypertension pathophysiology.
• Mallory-Weiss tear — a longitudinal mucosal laceration at the gastroesophageal junction caused by forceful, repeated retching or vomiting. Classic history: the patient vomited multiple times without blood, then developed hematemesis. Usually self-limiting and stops with conservative management.
• Erosive gastritis/esophagitis — mucosal inflammation from NSAIDs, alcohol, Helicobacter pylori infection, or critical illness (stress ulcers). High-risk ICU patients (mechanical ventilation, coagulopathy) receive prophylactic PPIs or H2-blockers to prevent stress ulceration.
• Dieulafoy lesion — an abnormally large submucosal artery that erodes through the mucosa without forming a visible ulcer. Rare but produces sudden, massive bleeding with no prior symptoms. Diagnosis requires endoscopy in the active bleeding phase.
• Gastric antral vascular ectasia (GAVE) — also called watermelon stomach because of its endoscopic appearance of red stripes radiating from the pylorus. Common in cirrhosis and autoimmune conditions. Causes slow, chronic blood loss rather than acute hemorrhage.
• Aortoenteric fistula — an abnormal tract between the aorta and the duodenum, almost always a late complication of prior aortic graft surgery. The classic presentation is a small “herald bleed” followed by catastrophic hemorrhage. Any patient with prior aortic surgery presenting with upper GI bleeding should be evaluated for fistula urgently.
• Malignancy — gastric and esophageal tumors with vascular erosion. Usually presents with occult or chronic slow bleeding rather than acute hemorrhage.

Presentation of upper GI bleeding

The hallmark presentations:

• Hematemesis — vomiting of blood. Bright red hematemesis indicates active, brisk bleeding with minimal contact time in the stomach. Coffee-ground emesis (dark, granular, resembling coffee grounds) indicates slower bleeding where gastric acid has oxidized hemoglobin to hematin — the bleeding is ongoing but less acute.
• Melena — black, tarry, malodorous stools. As little as 50–100 mL of blood entering the upper GI tract can produce melena. The dark color results from bacterial and enzymatic degradation of hemoglobin during 8+ hours of intestinal transit.
• Hematochezia from an upper source — bright red blood per rectum indicates a massive upper GI bleed (typically >1,000 mL) moving so rapidly through the GI tract that there is no time for digestion. This presentation carries significantly higher mortality than typical melena and mandates immediate aggressive resuscitation.

Hemodynamic changes reflect the volume of blood lost:

• <750 mL loss (<15% blood volume): resting tachycardia, mild anxiety — blood pressure may still be normal supine
• 750–1,500 mL loss (15–30%): orthostatic hypotension appears, tachycardia >100 bpm, anxiety and restlessness
• 1,500–2,000 mL loss (30–40%): supine hypotension, tachycardia >120 bpm, altered mental status, cool pale skin
• >2,000 mL loss (>40%): severe hypotension, lethargy or unresponsiveness, absent peripheral pulses — hemorrhagic shock

Lower GI bleeding

Lower GI bleeding originates distal to the ligament of Treitz. It accounts for approximately one-third of GI hemorrhage cases. Most episodes (80–85%) are self-limiting, though the 15–20% that continue bleeding or cause hemodynamic instability require urgent intervention.

Causes of lower GI bleeding

Diverticulosis is the most common cause in adults over 40. Diverticula form at points where the vasa recta (end-arterioles) penetrate the colonic wall — these are anatomically weak spots. When an artery within a diverticulum ruptures, the result is brisk, painless arterial bleeding. Painlessness is a key clinical feature that distinguishes diverticular bleeding from ischemic colitis or IBD.

Additional causes:

• Angiodysplasia (arteriovenous malformations) — abnormal, thin-walled dilated vessels in the colonic mucosa. The most common cause of lower GI bleeding in patients over 65. Associated with Heyde syndrome (concurrent aortic stenosis) and chronic kidney disease. Tends to cause recurrent, intermittent episodes.
• Colorectal cancer — tumor erosion into blood vessels. Typically causes occult or slow, chronic bleeding; occasionally presents as acute hematochezia. Any patient with unexplained lower GI bleeding and risk factors (age >50, family history, change in bowel habits) warrants colonoscopy.
• Inflammatory bowel disease — both Crohn’s disease and ulcerative colitis cause mucosal ulceration and bleeding. IBD bleeding is typically associated with diarrhea, cramping, and urgency. See the IBD nursing reference for full detail.
• Ischemic colitis — mucosal ischemia from reduced colonic blood flow, most often at the “watershed” zones (splenic flexure, rectosigmoid junction) where two arterial territories meet. Classic presentation: sudden cramping left lower quadrant pain followed by passage of maroon or bloody stool. Common in elderly patients with atherosclerosis.
• Hemorrhoids and anal fissures — the most common cause of visible rectal bleeding in adults. Bleeding is typically bright red, small volume, and associated with the bowel movement (on toilet paper or dripping into the bowl). These must be distinguished from more proximal pathology.
• Post-polypectomy bleeding — delayed hemorrhage occurring 5–14 days after colonoscopic polyp removal when the eschar falls off the cauterized vessel base.
• Meckel’s diverticulum — a true diverticulum of the ileum, typically presenting as painless lower GI bleeding in younger patients (under 30). Contains ectopic gastric mucosa that produces acid, ulcerating the adjacent ileal mucosa.

Presentation of lower GI bleeding

The typical presentation is hematochezia — bright red or maroon blood per rectum. Blood color provides localization clues:

• Bright red blood suggests a distal sigmoid or rectal source (minimal transit time)
• Maroon stools suggest a proximal colonic or distal small bowel source (longer transit, partial degradation)
• Melena can occur with proximal small bowel bleeding if transit is slow enough for degradation — this overlaps with upper GI bleed presentations

Most lower GI bleeds are painless (diverticular, angiodysplasia). Pain with bleeding raises concern for ischemic colitis, IBD, or infectious colitis. Patients requiring more than 2 units of packed red blood cells, who are hemodynamically unstable, or who have ongoing visible hemorrhage need urgent colonoscopy or CT angiography.

Nursing assessment

Systematic, serial assessment is the foundation of GI bleed management. Hemodynamic status can deteriorate rapidly, and the nurse is typically the first to detect early warning signs.

Vital signs and hemodynamic monitoring

• Heart rate: tachycardia is the earliest hemodynamic response to hemorrhage. A rate >100 bpm in any GI bleed patient warrants immediate escalation. Critically, beta-blockers (commonly prescribed for cirrhotic patients on propranolol for variceal prophylaxis) can mask tachycardia — never assume hemodynamic stability based on a normal heart rate alone in a beta-blocked patient.
• Orthostatic blood pressure: check for orthostatic hypotension — a drop of ≥20 mmHg systolic or ≥10 mmHg diastolic when the patient moves from supine to standing (or sitting). This indicates approximately 15% blood volume loss and frequently precedes any drop in supine blood pressure. This is a high-yield NCLEX finding.
• Respiratory rate and SpO2: tachypnea reflects compensatory response to reduced oxygen-carrying capacity. Monitor closely for aspiration risk in patients with active hematemesis or altered mental status.
• Temperature: fever in a GI bleed patient raises concern for bacterial translocation through a compromised gut barrier — a mechanism that leads to sepsis. Cirrhotic patients are particularly susceptible.
• Urine output: insert a Foley catheter for continuous monitoring. Target ≥0.5 mL/kg/hr as evidence of adequate renal perfusion.

Stool assessment

Document every stool for color, consistency, and estimated volume. Record the time between stools to assess ongoing loss rate.

• Melena: black, tarry, foul-smelling — upper GI or proximal lower GI source
• Hematochezia: bright red or maroon blood — lower GI source (or massive upper GI bleed)
• Coffee-ground output from NG tube: indicates partially digested blood in the stomach — the bleed is ongoing but not brisk

A change from melena to hematochezia signals rebleeding or acceleration of hemorrhage and requires immediate reassessment and escalation.

Abdominal assessment

• Inspection: abdominal distension, visible peristalsis, spider angiomata or caput medusae on the abdominal wall (signs of portal hypertension and variceal risk)
• Auscultation: hyperactive bowel sounds suggest blood in the GI tract (blood acts as a cathartic). Absent bowel sounds with tenderness raise concern for perforation.
• Palpation: tenderness, guarding, rigidity. A rigid, board-like abdomen with rebound tenderness indicates peritoneal contamination — this is a surgical emergency. Light percussion for ascites (shifting dullness) suggests cirrhosis with portal hypertension.

Nasogastric lavage

NG tube placement and lavage can help confirm an upper GI source when the presentation is ambiguous. Key interpretations:

• Bright red blood on aspiration: confirms active upper GI bleeding
• Coffee-ground material on aspiration: confirms upper GI source with slower bleeding
• Clear or bilious aspirate: does not rule out upper GI bleeding (a negative NG lavage has a false-negative rate of approximately 10–15% for upper GI bleed, because a post-pyloric source may not reflux)
• No bile on aspiration: the NG tube may not have passed the pylorus — the negative result cannot exclude upper GI pathology

Lab monitoring

Draw labs on arrival and repeat every 4–6 hours during active bleeding. Refer to the nursing lab values cheat sheet for normal ranges.

Nursing interventions

When a patient presents with GI bleeding, systematic prioritization prevents critical steps from being missed. The following table covers the priority interventions in order of urgency.

Risk stratification

Risk scores are used to determine urgency of endoscopy, need for hospitalization, and likelihood of adverse outcomes. Nurses encounter these scores during triage and handoff.

Glasgow-Blatchford Score (GBS) — upper GI bleed

Used pre-endoscopy to determine whether a patient needs inpatient management or can safely undergo outpatient endoscopy. Variables: BUN level, hemoglobin, systolic BP, heart rate, presence of melena, syncope, hepatic disease, and heart failure.

• Score 0: very low risk — outpatient endoscopy within 24 hours may be appropriate
• Score 1–6: intermediate risk — inpatient endoscopy within 24 hours
• Score ≥7: high risk — urgent inpatient endoscopy, ICU-level monitoring likely needed

The GBS has high sensitivity for identifying low-risk patients who can be managed safely without hospitalization — it is the preferred pre-endoscopy score.

AIMS65 Score — upper GI bleed mortality

AIMS65 predicts in-hospital mortality and guides resource allocation. Each letter represents one point:

• A — Albumin <3 g/dL
• I — INR >1.5
• M — altered Mental status (GCS <14, confusion, somnolence)
• S — Systolic BP <90 mmHg
• 65 — age ≥65 years

Score 0–1: low risk (mortality <1%). Score 2: ~3% mortality. Score 3: ~9% mortality. Score 4–5: mortality approaches 25%. Higher AIMS65 scores warrant early ICU or step-down placement, gastroenterology and surgery co-management, and proactive family communication about severity.

Rockall Score — upper GI bleed rebleeding

The Rockall Score has a pre-endoscopy component (age, comorbidities, hemodynamics) and a post-endoscopy component that adds endoscopic findings (source of bleeding, stigmata of hemorrhage). It predicts rebleeding risk and 30-day mortality. Unlike the GBS, it requires endoscopic data for the full score. The combined score ≥8 carries 40%+ rebleeding risk.

Oakland Score — lower GI bleed

The Oakland Score predicts safe discharge for lower GI bleed patients without further intervention. Variables include: age, sex, previous lower GI bleed admission, digital rectal exam findings, heart rate, systolic BP, and hemoglobin. Score ≤8 identifies patients appropriate for early discharge with outpatient colonoscopy. Higher scores indicate need for inpatient observation and urgent colonoscopy.

Pre-procedure nursing care

Most GI bleed patients proceed to endoscopy (EGD or colonoscopy) within hours of presentation. Pre-procedure nursing preparation directly affects procedure safety and quality.

Preparation for EGD (upper GI bleed)

• Confirm NPO status: document the time of last oral intake. Solids require 6 hours of fasting; clear liquids require 2 hours. If the patient ate recently and has ongoing hematemesis, intubation before EGD may be required.
• Erythromycin pre-medication: IV erythromycin 250 mg given 30–90 minutes before EGD accelerates gastric emptying by stimulating motilin receptors — it clears blood and clots from the stomach, improving endoscopic visualization. Verify the order and allergies (erythromycin is a macrolide antibiotic; cross-reactivity with azithromycin is possible).
• IV access verification: confirm both large-bore IVs are patent and functional. Endoscopy teams will need IV access for sedation.
• Consent: ensure written informed consent is obtained. If the patient has altered mental status, identify the healthcare proxy or surrogate decision-maker.
• Airway preparation: for patients with ongoing hematemesis, altered mental status, or a GBS ≥7, anticipate potential intubation before sedation. Have suction readily available at the bedside.
• Blood products available: confirm that typed and crossmatched blood is available in the blood bank before the patient is transported to the endoscopy suite.
• Vital sign baseline: document a full set of vitals immediately before transport. Communicate any trend changes (rising heart rate, falling BP) to the endoscopy team before the procedure begins.

Preparation for colonoscopy (lower GI bleed)

• Bowel preparation: most lower GI bleeds require a rapid purge preparation (polyethylene glycol solution, typically 4–6 liters over 2–4 hours) to clear stool and blood from the colon. Active, brisk lower GI bleeding may require CT angiography first if the patient is too unstable for bowel prep.
• Monitor for vasovagal responses: bowel prep causes large fluid shifts and stimulates vagal tone — monitor heart rate and blood pressure during prep administration.
• IV access and labs: same requirements as EGD. Ensure a type and crossmatch is current.
• Electrolyte monitoring: large-volume bowel prep can cause electrolyte shifts. Monitor sodium, potassium, and phosphate — particularly in patients with renal impairment.

Variceal bleeding: special considerations

Variceal hemorrhage deserves separate attention because the pathophysiology, management priorities, and mortality risk differ from nonvariceal GI bleeding. Esophageal varices develop when portal hypertension (most commonly from cirrhosis) forces blood through collateral venous pathways; the submucosal veins of the esophagus dilate under that pressure. When varices rupture, the hemorrhage is typically massive and carries 15–25% mortality per episode.

Pharmacologic management of variceal bleeding

• Octreotide is first-line – reduces portal pressure by inhibiting vasodilatory hormone release from the splanchnic circulation. Start immediately upon suspicion of variceal bleeding, before endoscopic confirmation.
• Antibiotics (ceftriaxone 1 g IV daily) are mandatory, not optional. GI bleeding in cirrhosis dramatically increases bacterial translocation and infection rates.
• Vasopressin with nitroglycerin is a second-line alternative if octreotide is unavailable. Concurrent nitroglycerin prevents coronary vasoconstriction and cardiac ischemia from vasopressin.

Endoscopic intervention

Endoscopic variceal ligation (EVL, or banding) is the gold standard for acute variceal hemorrhage. Rubber bands are placed around varices to induce necrosis and hemostasis. Sclerotherapy (injection of a sclerosant into the varix) is an alternative when banding is not technically feasible.

Balloon tamponade

The Sengstaken-Blakemore tube (or the Minnesota tube variant) is a last-resort bridge therapy when bleeding is uncontrolled and endoscopy cannot be performed or has failed. The tube has a gastric balloon and an esophageal balloon that compress the varices mechanically.

Critical nursing considerations for balloon tamponade:

• The patient must be intubated before insertion to protect the airway
• The gastric balloon is inflated first, then the esophageal balloon if bleeding continues
• Maximum esophageal inflation time is typically 24 hours – prolonged inflation causes esophageal necrosis and perforation
• Keep scissors at the bedside at all times to cut the tube and release the balloons immediately if the tube migrates and obstructs the airway
• This is temporary – definitive treatment (endoscopy or TIPS) must follow

TIPS procedure

Transjugular intrahepatic portosystemic shunt (TIPS) creates a channel between the hepatic vein and portal vein, decompressing portal pressure. TIPS is indicated for variceal bleeding refractory to endoscopic and pharmacologic therapy. Post-TIPS nursing priorities include monitoring for hepatic encephalopathy (the shunt diverts portal blood past the liver, reducing ammonia clearance) and assessing the shunt with Doppler ultrasound.

Secondary prophylaxis

After a variceal bleed episode, nonselective beta-blockers (propranolol or nadolol) reduce portal pressure and decrease the risk of rebleeding. These are combined with repeat endoscopic variceal ligation sessions until varices are obliterated. Administer lactulose as prescribed to prevent hepatic encephalopathy – the combination of GI blood (a protein load) and impaired hepatic clearance puts cirrhotic patients at high risk for encephalopathy after a variceal bleed.

Escalation triggers

Use structured SBAR-style handoff when escalating to the provider. Escalate immediately when:

• Heart rate >120 bpm or rising trend despite fluid resuscitation
• Systolic BP <90 mmHg or not responding to crystalloid boluses
• Urine output <0.5 mL/kg/hr for 2 consecutive hours
• Ongoing hematemesis or increasing hematochezia
• Altered level of consciousness – confusion, agitation, or decreasing Glasgow Coma Scale score
• Lactate >4 mmol/L or a rising serial lactate despite intervention
• Hemoglobin drop >2 g/dL between serial draws (4–6 hours apart)

Additional airway note: avoid non-invasive positive pressure ventilation (NIPPV) in actively vomiting patients – it increases aspiration risk. Any patient with active hematemesis and compromised airway protection needs endotracheal intubation before endoscopy, not a BiPAP trial.

Complications

GI bleeding carries several serious complications beyond the initial hemorrhage. Recognizing and preventing these complications is a core nursing responsibility.

Hemorrhagic shock

The most immediately life-threatening complication. Progressive blood loss depletes intravascular volume, reducing venous return and cardiac output. The compensatory response — tachycardia, peripheral vasoconstriction, increased respiratory rate — can maintain blood pressure temporarily. When compensation fails, blood pressure falls, perfusion drops below the threshold for aerobic metabolism, and lactic acidosis develops. Hemorrhagic shock progresses from Class I through Class IV with worsening hemodynamics at each stage. Massive transfusion protocol activation, surgical consultation, and interventional radiology embolization are the primary rescue strategies.

Rebleeding

Upper GI bleed rebleeding occurs in 10–20% of patients despite initial endoscopic hemostasis. High-risk endoscopic stigmata that predict rebleeding: active arterial spurting, visible nonbleeding vessel, and adherent clot overlying an ulcer. These patients require 72-hour hospitalization after hemostasis. Nursing vigilance — monitoring for new hematemesis, rising heart rate, or falling hemoglobin — is the primary detection method for rebleeding.

Aspiration pneumonia

Patients with active hematemesis, altered mental status, or requiring procedural sedation are at high risk. Aspiration of blood or gastric contents causes chemical pneumonitis that can progress to aspiration pneumonia or acute respiratory distress syndrome (ARDS). Prevention: head of bed elevation ≥30 degrees, intubation before EGD when airway is compromised, and continuous monitoring of SpO2 and respiratory rate post-procedure.

Hepatic encephalopathy (variceal bleeding)

In cirrhotic patients, a large GI bleed provides a substantial protein load (blood is approximately 17–20% protein). The compromised cirrhotic liver cannot clear the resulting ammonia surge. Bacterial translocation during the bleed adds further inflammatory burden. The result is hepatic encephalopathy — confusion, asterixis (flapping tremor), and in severe cases, coma. Prevention: lactulose administration to reduce ammonia absorption, rifaximin in recurrent cases, antibiotic prophylaxis to reduce bacterial translocation. Monitor orientation, asterixis, and serum ammonia.

Hypovolemic acute kidney injury

Sustained hypoperfusion from hemorrhage triggers prerenal AKI through afferent arteriolar vasoconstriction and reduced glomerular filtration. Signs: rising creatinine, falling urine output, concentrated urine (high specific gravity, low sodium). Management: adequate volume resuscitation, avoidance of nephrotoxic agents (NSAIDs, IV contrast in volume-depleted patients), and serial creatinine monitoring. The BUN:Cr ratio elevation seen in upper GI bleed is distinct from the equal elevation seen in true AKI — BUN:Cr >20:1 with normal or near-normal creatinine is the upper GI bleed pattern.

Electrolyte disturbances from massive transfusion

Rapid transfusion of large volumes of banked blood introduces citrate (a preservative that chelates calcium), potassium (released from hemolyzed cells in stored blood), and causes hypothermia (from cold blood products). Monitor ionized calcium, potassium, and temperature during massive transfusion. Hypocalcemia from citrate toxicity manifests as perioral tingling, tetany, and cardiac dysrhythmias — replace calcium chloride or gluconate as needed.

NCLEX tips

1. First priority is circulation, not endoscopy. Establish two large-bore IVs and initiate fluid resuscitation before any diagnostic procedure. NCLEX always prioritizes ABCs and hemodynamic stabilization.

2. BUN:Cr ratio >20:1 = upper GI source. Digested blood protein is absorbed in the small bowel, raising BUN disproportionately to creatinine. A normal ratio does not rule out lower GI bleeding.

3. Melena = digested blood = upper GI (or proximal lower GI with slow transit). The black, tarry appearance results from bacterial oxidation of hemoglobin over 8+ hours of transit.

4. Hematochezia from an upper source = massive bleed. Blood moving so fast through the GI tract that it cannot be digested. This patient needs the most aggressive intervention on the unit.

5. Orthostatic hypotension is an early and important hemorrhage sign. A drop of ≥20 mmHg systolic on standing indicates ~15% blood volume loss and often appears before any drop in supine BP. Assess every GI bleed patient who can safely stand.

6. Octreotide is the first-line drug for variceal bleeding. It reduces portal pressure by inhibiting splanchnic vasodilator release. Beta-blockers (propranolol, nadolol) are for secondary prophylaxis after the acute episode — never for acute management.

7. Do not trust a normal H&H in acute hemorrhage. Hemodilution takes 24–72 hours to equilibrate. A patient who lost 1,500 mL of blood in the last hour may still have a hemoglobin of 14 g/dL. Assess hemodynamics and trend, not a single lab value.

8. Coffee-ground emesis = slow, partially digested bleeding. Gastric acid converts hemoglobin to hematin, producing the dark granular material. This indicates the bleed has been ongoing but is currently not brisk.

9. Know the anticoagulant reversal agents. Warfarin → PCC (four-factor prothrombin complex concentrate). Heparin → protamine sulfate. Dabigatran → idarucizumab. Rivaroxaban/apixaban → andexanet alfa. Questions about GI bleeding in anticoagulated patients will test whether you know these pairings.

10. Antibiotics in cirrhotic GI bleed are mandatory, not optional. Bacterial infection in cirrhosis is directly associated with higher rebleeding rates and mortality. Any cirrhotic patient with GI bleeding must receive IV antibiotic prophylaxis regardless of current signs of infection.

11. Track stool color changes as a bleeding trajectory indicator. A shift from melena to formed brown stools suggests the bleed is resolving. A shift from melena to hematochezia suggests the bleed is accelerating – escalate urgently.

NANDA-I nursing care plans for GI bleed

GI bleeding generates overlapping nursing diagnoses that span fluid status, cardiovascular stability, physical endurance, psychosocial response, and patient education. The five plans below cover the core clinical priorities nurses manage from admission through discharge.

1. Deficient fluid volume

NANDA-I diagnosis: Deficient fluid volume

Related to: Active gastrointestinal hemorrhage; fluid shifting from intravascular to third spaces

Evidenced by: Tachycardia; orthostatic hypotension (systolic drop ≥20 mmHg on standing); decreased urine output; falling hemoglobin and hematocrit on serial draws; dry mucous membranes; patient report of dizziness

Goal: Patient will maintain hemodynamic stability as evidenced by heart rate below 100 bpm, systolic BP above 90 mmHg, and urine output ≥0.5 mL/kg/hr throughout the admission.

Interventions and rationale:

• Establish two large-bore peripheral IVs (16–18 gauge) immediately. IV flow rate follows Poiseuille’s law – catheter radius is the dominant variable. A 16-gauge catheter delivers crystalloid and blood products significantly faster than an 18-gauge. Large-bore access is the rate-limiting factor in acute hemorrhage resuscitation.
• Initiate isotonic crystalloid infusion (normal saline or lactated Ringer’s) while blood products are prepared. Crystalloid restores intravascular volume temporarily. Avoid aggressive over-resuscitation in variceal bleeding – excess volume raises portal pressure and can precipitate rebleeding.
• Monitor orthostatic vital signs every 1–2 hours during active bleeding. A systolic drop of ≥20 mmHg or diastolic drop of ≥10 mmHg on standing indicates approximately 15% blood volume loss, typically preceding supine hypotension. Document findings using positional sequence (supine → sitting → standing) with heart rate and BP recorded at each position.
• Insert a Foley catheter; monitor urine output continuously. Target output ≥0.5 mL/kg/hr. A falling urine output despite IV fluids signals inadequate perfusion or ongoing hemorrhage – escalate to the provider immediately.
• Draw serial hemoglobin and hematocrit every 4–6 hours. A single normal H&H in acute hemorrhage is unreliable: hemodilution takes 24–72 hours to equilibrate. Trending the values over time is far more informative than any single result.
• Administer packed red blood cells per protocol. Transfuse when hemoglobin falls below 7 g/dL (or 8 g/dL in cardiovascular disease). The ACG restrictive transfusion strategy (targeting Hgb 7–9 g/dL) demonstrates lower rebleeding rates and better survival than a liberal strategy. Monitor hemoglobin response after each unit.
• Activate massive transfusion protocol (MTP) for hemodynamic instability unresponsive to initial resuscitation. MTP delivers PRBCs, FFP, and platelets in a balanced 1:1:1 ratio to prevent dilutional coagulopathy during large-volume transfusion. Notify the blood bank early.

Evaluation: Patient’s heart rate, blood pressure, and urine output return to or remain within target ranges. Serial hemoglobin trends stabilize. No new episodes of hematemesis or hematochezia. Patient denies dizziness on standing after orthostatic assessment.

2. Risk for decreased cardiac output

NANDA-I diagnosis: Risk for decreased cardiac output

Related to: Hemorrhagic shock from ongoing GI blood loss; compensatory tachycardia leading to reduced diastolic filling time; electrolyte disturbances from massive transfusion (hypocalcemia, hyperkalemia)

Goal: Patient will maintain adequate cardiac output as evidenced by stable blood pressure, heart rate below 110 bpm, warm and dry skin, and absence of dysrhythmias on cardiac monitoring throughout hospitalization.

Interventions and rationale:

• Initiate continuous cardiac monitoring on admission. Tachycardia is the earliest hemodynamic indicator of hemorrhage. Continuous monitoring detects dysrhythmias from hypoxia, electrolyte shifts during massive transfusion, or underlying cardiac comorbidities that complicate resuscitation.
• Recognize masked tachycardia in beta-blocked patients. Cirrhotic patients on propranolol or nadolol for variceal prophylaxis cannot mount the expected tachycardic response to hemorrhage. A “normal” heart rate of 70 bpm in a beta-blocked patient with active bleeding does not indicate hemodynamic stability – assess perfusion through urine output, mental status, and skin temperature instead.
• Monitor serum lactate serially. Lactate above 2 mmol/L indicates tissue hypoperfusion; above 4 mmol/L signals high mortality risk and requires urgent escalation. A rising lactate despite resuscitation indicates ongoing hemorrhage rather than adequate volume replacement.
• Monitor ionized calcium during massive transfusion. Banked blood contains citrate as a preservative; citrate chelates calcium during rapid transfusion. Hypocalcemia manifests as perioral tingling, tetany, and cardiac dysrhythmias. Replace calcium chloride or gluconate as needed per protocol.
• Assess skin color, temperature, and capillary refill every 1–2 hours. Cool, pale, clammy skin with delayed capillary refill (>3 seconds) indicates peripheral vasoconstriction from reduced cardiac output. Document changes and escalate.
• Calculate and document Blatchford and AIMS65 scores. These scores quantify rebleeding risk and mortality. Patients with GBS ≥7 or AIMS65 ≥3 require ICU-level monitoring and early gastroenterology and surgery co-management – communicate scores clearly during SBAR handoff.
• Escalate immediately when systolic BP falls below 90 mmHg or fails to respond to two crystalloid boluses. This threshold, combined with ongoing hemorrhage, represents decompensated shock – the window for intervention narrows rapidly.

Evaluation: Patient maintains systolic BP above 90 mmHg, heart rate below 110 bpm, and normal sinus rhythm on monitoring. Serum lactate trends downward with resuscitation. Ionized calcium remains within normal range. Skin warm and dry.

3. Activity intolerance

NANDA-I diagnosis: Activity intolerance

Related to: Anemia from acute blood loss; reduced oxygen-carrying capacity; orthostatic hypotension; deconditioning from bed rest during acute phase

Evidenced by: Patient reports fatigue and weakness; dyspnea or increased heart rate with minimal movement; hemoglobin below normal reference range; dizziness when attempting to stand; SpO2 decrease with exertion

Goal: Patient will tolerate progressive activity as evidenced by heart rate increase of no more than 20 bpm from baseline with ambulation, absence of dyspnea at rest, and SpO2 ≥94% throughout activity by the time of discharge.

Interventions and rationale:

• Implement fall precautions and bedside call light education on admission. Orthostatic hypotension from volume depletion significantly increases fall risk when the patient attempts to stand. Instruct the patient to call for assistance before getting out of bed – this is a safety priority, not a preference.
• Maintain supplemental oxygen as needed to keep SpO2 ≥94%. Anemia reduces hemoglobin available for oxygen transport. Supplemental oxygen partially compensates by increasing dissolved oxygen in plasma, supporting tissue oxygenation during active hemorrhage.
• Provide complete assistance with ADLs during the acute phase (Hgb <8 g/dL). Self-care activities increase myocardial oxygen demand. When oxygen-carrying capacity is severely limited, minimizing exertion preserves cardiac reserves for vital organ perfusion.
• Monitor heart rate and SpO2 before and after any activity. A heart rate increase of more than 20 bpm or SpO2 drop below 94% with minimal activity signals insufficient oxygen delivery – reduce activity level and reassess.
• Advance activity progressively as hemoglobin stabilizes above 8 g/dL. Begin with dangling legs at the bedside, then sitting in a chair, then supervised ambulation. Document tolerance at each step and communicate to the physical therapy team.
• Administer PRBCs per protocol to restore oxygen-carrying capacity. Transfusion to the target hemoglobin directly addresses the physiologic cause of activity intolerance. Monitor for transfusion reactions (fever, rigors, back pain, hemoglobinuria) and assess hemoglobin response 1–2 hours post-transfusion.
• Coordinate with dietary services for iron-rich nutrition post-acute phase. Once oral intake resumes, iron-containing foods support erythropoiesis. In H. pylori-associated peptic ulcer disease, eradication therapy removes the ongoing source of mucosal inflammation and blood loss.

Evaluation: Patient tolerates sitting at the bedside without dizziness or SpO2 decline. Heart rate remains within 20 bpm of baseline with assisted ambulation. Patient verbalizes understanding of fall precautions and calls for assistance before standing.

4. Anxiety

NANDA-I diagnosis: Anxiety

Related to: Acute illness with life-threatening hemorrhage; witnessing hematemesis; uncertainty regarding diagnosis, procedures, and prognosis; ICU or high-acuity environment; separation from family

Evidenced by: Patient verbalization of fear; restlessness or difficulty remaining still; tachycardia above expected hemodynamic response; diaphoresis; difficulty following instructions; family members expressing distress

Goal: Patient will verbalize reduced anxiety as evidenced by reporting fear level of ≤4/10 on a 0–10 scale, participating in pre-procedure preparation, and demonstrating ability to follow safety instructions by end of initial assessment and orientation.

Interventions and rationale:

• Introduce yourself and explain every intervention before performing it. GI bleeds are frightening – vomiting blood is among the most alarming symptoms a person can experience. Brief, calm explanations before each action reduce uncertainty, which is the primary driver of acute anxiety in the clinical setting.
• Provide a consistent clinical contact. Frequent staff changes amplify anxiety. When possible, assign consistent nursing staff and introduce the gastroenterology team early. Familiar faces reduce the sense of loss of control.
• Explain the endoscopy procedure in plain language. Many patients have never undergone EGD. Describe what they will experience: sedation, throat spray, the scope passing while they are comfortable and unaware. Provide a written summary if available. Patients who understand the procedure report lower pre-procedural anxiety.
• Allow family presence during stable periods when clinically safe. Family presence is anxiolytic. Involve the support person in education and provide a contact number for updates during procedures. Communicate prognosis clearly and with appropriate framing.
• Assess and differentiate anxiety from hemorrhagic shock symptoms. Restlessness and tachycardia occur in both anxiety and hypovolemic shock. Do not attribute tachycardia to anxiety alone in an actively bleeding patient – reassess hemodynamics concurrently and escalate if any clinical doubt exists.
• Administer anxiolytic or sedation agents as ordered, with monitoring. Benzodiazepines or procedural sedation may be appropriate pre-endoscopy. Monitor respiratory rate and SpO2 continuously – these agents can suppress respiratory drive, and the combination of active bleeding and sedation requires close airway surveillance.

Evaluation: Patient reports anxiety level of ≤4/10. Patient participates cooperatively with nursing assessments. Family expresses understanding of the plan of care. Patient demonstrates no behavioral or physiologic indicators of uncontrolled anxiety (persistent agitation, inability to follow safety instructions).

5. Deficient knowledge

NANDA-I diagnosis: Deficient knowledge (regarding GI bleed etiology, endoscopy preparation, medication adherence, return precautions, and lifestyle modification)

Related to: New diagnosis; first GI bleed episode; limited prior exposure to endoscopic procedures; complex medication regimen with multiple new prescriptions; health literacy barriers

Evidenced by: Patient verbalization of questions or misconceptions; inability to state return precautions; failure to list medications; report of prior NSAID or alcohol use without awareness of contribution to bleeding

Goal: Patient will demonstrate understanding of discharge instructions as evidenced by accurately describing at least four return precautions, naming prescribed medications and their purpose, and stating two lifestyle modifications to reduce rebleeding risk before discharge.

Interventions and rationale:

• Teach return precautions explicitly before discharge. Patients must know to return to the ED for: black, tarry, foul-smelling stools (melena); vomiting blood or coffee-ground material; lightheadedness or syncope when standing; significant fatigue or pallor. Written discharge instructions reinforce verbal education, particularly for patients who were anxious or sedated during the hospitalization.
• Explain the PPI prescription and the consequence of early discontinuation. Patients stopping PPIs prematurely lose the mucosal protection that reduces rebleeding risk. Frame adherence as a direct rebleeding-prevention strategy: “this medication keeps the sore in your stomach from reopening.” For PUD patients, clarify that the PPI course typically runs 8 weeks for gastric ulcers and 4–6 weeks for duodenal ulcers.
• Teach H. pylori eradication therapy if indicated. H. pylori is identified in approximately 70–80% of duodenal ulcers and 40–60% of gastric ulcers. Eradication requires a complete antibiotic course (triple or quadruple therapy per local resistance patterns). Partial compliance leads to treatment failure and persistent ulcer recurrence. Confirm understanding of each agent in the regimen.
• Counsel on NSAID and aspirin avoidance. NSAIDs inhibit cyclooxygenase, reducing prostaglandin synthesis and impairing mucosal protection. Even low-dose aspirin doubles the risk of peptic ulcer bleeding. If NSAIDs are medically necessary, co-prescribing a PPI is standard; explain this trade-off to the patient so they do not stop the PPI independently.
• Provide structured alcohol cessation counseling for alcohol-related bleeds. Alcohol contributes to GI bleeding through multiple pathways: direct mucosal erosion, impaired platelet function, and cirrhosis-mediated variceal development. Refer to addiction medicine or social work for formal cessation support. Frame abstinence as a direct, modifiable risk factor – not a moral judgment.
• Explain the endoscopy follow-up plan. For variceal bleeds, repeat banding sessions are scheduled every 1–4 weeks until varices are obliterated – patients need to understand this is a process, not a one-time intervention. For ulcer bleeds, repeat EGD may be indicated at 6–8 weeks to confirm healing for gastric ulcers (to rule out malignancy) and to verify H. pylori eradication. For variceal patients, also educate on beta-blocker adherence as secondary prophylaxis.
• Assess health literacy and use teach-back. Ask the patient to explain the discharge instructions in their own words. Correct misconceptions without judgment. Provide discharge materials in the patient’s primary language when possible. Involve a family member or caregiver in the teach-back session.

Evaluation: Patient accurately states four or more return precautions. Patient names all prescribed discharge medications and explains their purpose. Patient states two dietary or lifestyle modifications (NSAID avoidance, alcohol cessation, dietary triggers if applicable). Patient demonstrates correct understanding of follow-up endoscopy timing.

Frequently asked questions

What is the nursing priority for a patient with a GI bleed?

The immediate priority is circulatory stabilization: establish two large-bore peripheral IVs (16–18 gauge), initiate crystalloid resuscitation, and place the patient on continuous cardiac monitoring. Airway protection is assessed concurrently, particularly in patients with active hematemesis or altered mental status who may require intubation before endoscopy.

What are the nursing interventions for upper GI bleed?

Key interventions include establishing large-bore IV access, placing the patient NPO, initiating an IV proton pump inhibitor (pantoprazole 80 mg bolus then 8 mg/hr infusion), and administering octreotide if variceal bleeding is suspected. Transfuse packed red blood cells when hemoglobin falls below 7 g/dL. Serial hemoglobin and hematocrit monitoring every 4–6 hours tracks ongoing loss; orthostatic vital signs quantify volume depletion.

What NANDA diagnoses apply to GI bleed?

The most clinically relevant NANDA-I diagnoses include Deficient fluid volume related to active hemorrhage, Risk for decreased cardiac output related to hemorrhagic shock, Activity intolerance related to anemia and reduced oxygen-carrying capacity, Anxiety related to acute illness and hematemesis, and Deficient knowledge related to GI bleed triggers, endoscopy procedures, and discharge precautions.

What is a normal hemoglobin for a GI bleed patient before transfusion?

Per ACG guidelines, the transfusion threshold for hemodynamically stable GI bleed patients is a hemoglobin below 7 g/dL. In patients with cardiovascular disease, the threshold rises to below 8 g/dL. A restrictive transfusion strategy – targeting 7 g/dL – demonstrates lower rebleeding rates and better survival than a liberal strategy, particularly in variceal bleeding where over-transfusion raises portal pressure.

How do you assess GI bleed severity as a nurse?

Severity assessment combines hemodynamic parameters, serial lab trends, and validated risk scores. Check orthostatic blood pressure – a drop of 20 mmHg systolic indicates approximately 15% volume loss. Monitor heart rate trends and track serial hemoglobin every 4–6 hours. The Glasgow-Blatchford Score quantifies pre-endoscopy risk in upper GI bleeds; the AIMS65 score predicts in-hospital mortality. Familiarity with both guides urgency decisions and SBAR handoff communication.

What medications are used in GI bleed management?

For nonvariceal upper GI bleeds, IV pantoprazole (80 mg bolus, then 8 mg/hr infusion) is the cornerstone, raising gastric pH to stabilize clot formation. For suspected variceal bleeds, octreotide (50 mcg bolus, then 50 mcg/hr) reduces portal pressure and starts before endoscopic confirmation. Cirrhotic patients receive ceftriaxone 1 g IV daily for 7 days to prevent bacterial translocation. Anticoagulation reversal agents – four-factor PCC for warfarin, idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors – are used when active hemorrhage occurs in anticoagulated patients.

What is the difference between upper and lower GI bleed nursing care?

Upper GI bleeds (proximal to the ligament of Treitz) present with hematemesis or melena and require IV PPI, possible octreotide, and urgent EGD preparation including erythromycin pre-medication to clear the stomach. Lower GI bleeds present with hematochezia and require bowel preparation for urgent colonoscopy, with CT angiography reserved for patients too unstable for prep. BUN:Cr ratio elevation above 20:1 points to an upper source; a normal ratio favors lower GI pathology.

What education do you give a patient after a GI bleed?

Discharge education covers return precautions (black tarry stools, vomiting blood, lightheadedness on standing), medication adherence (PPI therapy, H. pylori eradication if indicated), and avoidance of NSAIDs and alcohol. For variceal bleeds, education includes alcohol cessation counseling, the role of nonselective beta-blockers in secondary prophylaxis, and the importance of follow-up endoscopy for variceal ligation until obliteration is confirmed.

Related nursing references

• Peptic ulcer disease nursing reference — PUD pathophysiology, H. pylori eradication therapy, gastric vs duodenal comparison
• Cirrhosis nursing reference — portal hypertension, Child-Pugh staging, variceal prophylaxis, hepatic encephalopathy
• Nursing lab values cheat sheet — normal ranges and clinical significance for all labs in this article
• Pancreatitis nursing reference — differential for abdominal pain and epigastric presentations
• Diverticulitis nursing reference — diverticular disease and its relationship to lower GI bleed
• Sepsis nursing reference — bacterial translocation sepsis in cirrhotic GI bleed
• AKI nursing reference — hypovolemic AKI from hemorrhage, BUN:Cr monitoring

References

1. Laine L, Jensen DM. “Management of patients with ulcer bleeding.” American Journal of Gastroenterology. 2012;107(3):345–360. doi:10.1038/ajg.2011.480
2. Villanueva C, Colomo A, Bosch A, et al. “Transfusion strategies for acute upper gastrointestinal bleeding.” New England Journal of Medicine. 2013;368(1):11–21. doi:10.1056/NEJMoa1211801
3. Barkun AN, Almadi M, Kuipers EJ, et al. “Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group.” Annals of Internal Medicine. 2019;171(11):805–822. doi:10.7326/M19-1795
4. Blatchford O, Murray WR, Blatchford M. “A risk score to predict need for treatment for upper-gastrointestinal haemorrhage.” The Lancet. 2000;356(9238):1318–1321. doi:10.1016/S0140-6736(00)02816-6
5. Rockall TA, Logan RF, Devlin HB, Northfield TC. “Risk assessment after acute upper gastrointestinal haemorrhage.” Gut. 1996;38(3):316–321. doi:10.1136/gut.38.3.316
6. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases. “Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.” Hepatology. 2007;46(3):922–938. doi:10.1002/hep.21907
7. Strate LL, Gralnek IM. “ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding.” American Journal of Gastroenterology. 2016;111(4):459–474. doi:10.1038/ajg.2016.41
8. Oakland K, Isherwood J, Lahiff C, et al. “Derivation and validation of a novel risk score for safe discharge after acute lower gastrointestinal bleeding: a modelling study.” The Lancet Gastroenterology and Hepatology. 2017;2(9):635–643. doi:10.1016/S2468-1253(17)30150-4
9. Sung JJ, Tsoi KK, Ma TK, Yung MY, Lau JY, Chiu PW. “Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases.” American Journal of Gastroenterology. 2010;105(1):84–89. doi:10.1038/ajg.2009.507
10. Dworzynski K, Pollit V, Kelsey A, Higgins B, Palmer K; Guideline Development Group. “Management of acute upper gastrointestinal bleeding: summary of NICE guidance.” BMJ. 2012;344:e3412. doi:10.1136/bmj.e3412
11. Gralnek IM, Stanley AJ, Morris AJ, et al. “Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) guideline — update 2021.” Endoscopy. 2021;53(3):300–332. doi:10.1055/a-1369-5274
12. Aims65 score — Saltzman JR, Tabak YP, Hyett BH, Sun X, Travis AC, Johannes RS. “A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding.” Gastrointestinal Endoscopy. 2011;74(6):1215–1224. doi:10.1016/j.gie.2011.06.024
13. de Franchis R; Baveno VI Faculty. “Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension.” Journal of Hepatology. 2015;63(3):743–752. doi:10.1016/j.jhep.2015.05.022
14. Lau JYW, Sung J, Hill C, Henderson C, Howden CW, Metz DC. “Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality.” Digestion. 2011;84(2):102–113. doi:10.1159/000323937
15. Stanley AJ, Laine L, Dalton HR, et al. “Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study.” BMJ. 2017;356:i6432. doi:10.1136/bmj.i6432